Agios Pharmaceuticals (AGIO) Q3 2024 earnings summary

Executive summary

• Achieved $1.1 billion in milestone payments following FDA approval of vorasidenib, resulting in net income of $947.9 million for Q3 2024 and a cash position of $1.7 billion at quarter-end.

• Positive phase 3 data for mitapivat in thalassemia and PK deficiency, with full enrollment completed for the phase 3 RISE UP sickle cell disease study.

• Preparing for potential launches of mitapivat in thalassemia (2025) and sickle cell disease (2026), with robust commercial and regulatory strategies underway.

• Tebapivat (AG-946) received FDA orphan drug designation for MDS and phase 2b study initiated.

• Entered distribution agreement for PYRUKYND® in the GCC region and expanded preclinical pipeline with Alnylam collaboration.

Financial highlights

• Net income for Q3 2024 was $947.9 million, compared to a net loss of $91.3 million in Q3 2023, driven by $1.1 billion in vorasidenib-related payments.

• PYRUKYND® net revenue for Q3 2024 was $9.0 million, up 22% year-over-year and 4% sequentially from Q2 2024.

• R&D expenses were $72.5 million, down from $81.8 million in Q3 2023; SG&A expenses rose to $38.5 million from $25.8 million.

• Cash, cash equivalents, and marketable securities totaled $1.7 billion as of September 30, 2024, up from $806.4 million at year-end 2023.

• Recognized $889.1 million gain on sale of Vorasidenib Royalty Rights and $200 million milestone payment in Q3 2024.

Outlook and guidance

• sNDA submission for mitapivat in thalassemia expected by year-end, targeting a broad label for all adult subtypes.

• U.S. launch of mitapivat in thalassemia anticipated in 2025, with sickle cell disease launch targeted for 2026.

• Cash position expected to fund operations and product launches for at least the next twelve months.

• Ongoing expansion of commercial and medical teams to support upcoming launches.

• Additional clinical data to be presented at the ASH Congress in December 2024.